In vitro inhibition of ?-chymotryptic activity by phenolic compounds

2001 ◽  
Vol 81 (15) ◽  
pp. 1512-1521 ◽  
Author(s):  
Sascha Rohn ◽  
Harshadrai M Rawel ◽  
Nadine Pietruschinski ◽  
J�rgen Kroll
2011 ◽  
Vol 77 (6) ◽  
pp. 494-499 ◽  
Author(s):  
Murat Şentürk ◽  
İlhami Gülçin ◽  
Şükrü Beydemir ◽  
Ö. İrfan Küfrevioğlu ◽  
Claudiu T. Supuran

2011 ◽  
Vol 21 (14) ◽  
pp. 4259-4262 ◽  
Author(s):  
Sevim Beyza Öztürk Sarikaya ◽  
Fevzi Topal ◽  
Murat Şentürk ◽  
İlhami Gülçin ◽  
Claudiu T. Supuran

Planta Medica ◽  
2013 ◽  
Vol 79 (13) ◽  
Author(s):  
K Sykłowska-Baranek ◽  
A Pietrosiuk ◽  
K Graikou ◽  
H Damianakos ◽  
M Jeziorek ◽  
...  

1973 ◽  
Vol 30 (02) ◽  
pp. 334-338 ◽  
Author(s):  
Felisa C. Molinas

SummaryIt has been postulated that the high phenol and phenolic acids plasmatic levels found in patients with chronic renal failure are contributory factors in the abnormal platelet function described in these patients. This hypothesis was corroborated by “in vitro” studies showing the deleterious effect of these compounds on certain platelet function after pre-incubation of PRP with phenol and phenolic compounds. The present studies were conducted to determine the influence of phenolic compounds on platelet release reaction. It was found that phenol inhibited from 62.5 to 100% the effect of the aggregating agents thrombin, adrenaline and ADP on platelet 5-HT-14C release. The phenolic acids p-, m-, and o-HPAA inhibited from 36.35 to 94.8% adrenaline and ADP-induced platelet 5-HT-14C release. Adrenaline-induced platelet ADP release was inhibited from 27.45 to 38.10% by the phenolic compounds. These findings confirm the hypothesis that phenolic compounds interfere with platelet function through the inhibition of the release reaction.


2007 ◽  
Vol 45 (08) ◽  
Author(s):  
D Hagelauer ◽  
O Kelber ◽  
D Weiser ◽  
S Laufer ◽  
H Heinle

Sign in / Sign up

Export Citation Format

Share Document